Most Active

CG Oncology Stock Hits All-Time High After PIVOT-006 Phase 3 Trial Shows 68% Cut in Bladder Cancer Recurrence Risk

Read this in the Market Flux app

CG Oncology Inc. $CGON

$84.90+14.15%as of publication

5D Change
+13.37%
Notional
$706.06M

CG Oncology shares surged to an all-time intraday high of $92.00 on Monday after the company reported positive topline results from its PIVOT-006 Phase 3 registrational trial, with its experimental bladder cancer therapy cutting the risk of tumor recurrence by 68% versus the control arm. The result, described by analysts as exceeding even the most bullish expectations, sent the stock up roughly 30% from its prior close and placed it on pace for a record closing high, bringing its total gain to 291% above its IPO price.

The trial tested adjuvant intravesical cretostimogene grenadenorepvec against surveillance or TURBT alone in 367 patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer, using a randomized 1:1 open-label design. The primary endpoint of recurrence-free survival was met with a hazard ratio of 0.32 (95% confidence interval: 0.23 to 0.45; p less than 0.0001), a statistically significant and clinically meaningful result. The safety profile was described as compelling, with no Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations. Arthur Kuan, chairman, president, and CEO of CG Oncology, called the outcome a defining milestone for the company, and topline results were scheduled for a late-breaking podium presentation.

Options market activity reflected the surge in investor interest, with 14,793 contracts trading in CGON by late afternoon, representing approximately 1.5 million underlying shares and roughly 122 times normal volume. The stock's advance came on a broadly weak day for equities, with the Nasdaq Composite falling around 500 points.

© AI-generated summary is provided by Market Flux

Sources

  1. ReutersCG Oncology's immunotherapy reduces risk of tumor recurrence in bladder cancer trial
  2. Yahoo FinanceCG Oncology’s stock up as gene therapy gains second win in NMIBC
  3. TheTradeXchange$CGON - PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
  4. OpenOutcrier$CGON (+29.8% pre) CG Oncology Phase 3 trial shows 68% recurrence risk cut in bladder cancer
  5. Marketwirenews$CGON - PIVOT006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in RecurrenceFree Survival RFS for IntermediateRisk and HighGrade Ta NonMuscle Invasive Bladder Cancer NMIBC – Cretostimogene reduced the risk of recurrence by 68%, demonstrating a statistically significant and clinically meaningful benefit with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001) – Compelling safety and tolerability results, no Grade 3 or higher TRAEs and no tre... News & Disclaimer
  6. BenzingaH World Group Posts Upbeat Q3 Earnings, Joins CG Oncology, TELUS And Other Big Stocks Moving Higher On Monday
  7. Investors Business DailyCG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out
  8. Seeking AlphaCG Oncology rises on phase 3 data for bladder cancer immunotherapy
Show 7 more
  1. JonnajarianRebel’s Edge 🏴‍☠️ 1pm Line up: #VIX $TU $SNDK $CGON $SMMT 🏈 NAJARIAN SPORTS 🏴‍☠️ with @petenajarian Parity is here in college football with only two undefeated teams left, is it the craziest year ever? Are the 49ers and Jacksonville the best of the NFC and AFC? #ITSNOTANOPTION 📙
  2. BarronsThis Biotech Stock Is Up 291% From Its IPO Price. It's On Pace for a Record Closing High.
  3. BarronsonlineCG Oncology stock is on pace for a record closing high after ‘best case’ Phase 3 trial results for its bladder cancer treatment.
  4. MarketRebelsSTARTS NOW! Rebel’s Edge 🏴‍☠️ 1pm Line up: #VIX $TU $SNDK $CGON $SMMT 🏈 NAJARIAN SPORTS 🏴‍☠️ with @petenajarian Parity is here in college football with only two undefeated teams left, is it the craziest year ever? Are the 49ers and Jacksonville the best of the NFC and AFC? #ITSNOTANOPTION 📙
  5. Schaeffers Research2 Cancer-Drug Developers Seeing Unusual Options Volume
  6. NasdaqNoteworthy Monday Option Activity: CGON, SLS, TGT
  7. BPharmCatalyst$CRDF reported that onvansertib, in combination with FOLFIRI and bevacizumab, received Fast Track designation from the FDA for first-line RAS-mutated metastatic colorectal cancer. The designation builds on randomized Phase 2 trial data showing a 72.2% confirmed overall response rate, compared with 42.1% in the standard-of-care group. This regulatory progress outlines the steps leading toward a pivotal registrational trial, making the planned Phase 3 study initiation and progression-free survival durability key future valuation drivers. $CRDF $CGON $CNSP $XTNT $LXEO $MIST $AKAN $CVM $MIST $VRAX For more biotech updates, join us on 🔗 BioPharmCatalyst 📰 Articles section